CAM
CASC

ClariVest Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

ClariVest Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-37,678
Closed -$370K – 760
2016
Q3 		$370K Sell
37,678
-14,316
-28% -$102K 0.01% 421
2016
Q2 		$294K Buy
51,994
+11,661
+29% +$79.2K 0.01% 430
2016
Q1 		$308K Buy
40,333
+23,366
+138% +$180K 0.01% 412
2015
Q4 		$226K Buy
16,967
+2,767
+19% +$47.6K 0.01% 444
2015
Q3 		$234K Buy
14,200
+83
+0.6% +$1.7K 0.01% 404
2015
Q2 		$316K Buy
+14,117
New +$223K 0.01% 371

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

ClariVest Asset Management's CASC Position: Q4 2016 in Review

ClariVest Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 37,678 shares — an estimated $370K sold.

ClariVest Asset Management first reported a position in CASC in Q2 2015 and held it in 6 quarters. The position peaked at $370K in Q3 2016. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • ClariVest Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • ClariVest Asset Management sold 37,678 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $370K.
  • ClariVest Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
  • ClariVest Asset Management's Cascadian Therapeutics, Inc. position peaked at $370K in Q3 2016.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on ClariVest Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.